Pro-haloacetate Nanoparticles for Efficient Cancer Therapy via Pyruvate Dehydrogenase Kinase Modulation

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Pyruvate dehydrogenase kinase (PDK) is a key enzyme that promotes cancer cell survival by inhibiting mitochondria-dependent apoptosis.
• Haloacetic acids are explored as potential anticancer agents targeting PDK.

Purpose of the Study:

• To develop novel haloacetic acid-based anticancer agents that inhibit PDK.
• To investigate the efficacy of these agents in various cancer models.

Main Methods:

• Molecular docking studies to identify potent PDK2 binders.
• In silico screening for prodrug development.
• Self-assembly of prodrugs into nanoparticles.
• In vitro and in vivo cancer models for efficacy testing.
• Pyruvate dehydrogenase (PDH) assay for mechanistic confirmation.

Main Results:

• Mono- and dihaloacetates were identified as potent PDK2 binders.
• Phospholipid prodrug nanoparticles were successfully synthesized.
• The novel agents demonstrated significant anticancer activity in vitro and in vivo.
• Mechanism of action confirmed to involve reactivation of mitochondria-dependent apoptosis.

Conclusions:

• Haloacetic acid-based nanoparticle prodrugs are effective PDK inhibitors.
• These agents show promise for cancer regression by inducing mitochondria-dependent apoptosis.
• Further development of these novel anticancer agents is warranted.